3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Breast
1
Conditions
Pain
3
Neuralgia
3
Breast Neoplasms
3
Seizures
1
Pinealoma
1
Oligodendroglioma
1
Obesity
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Myotoxicity
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Inflammation
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Earache
1
Drug-Related Side Effects and Adverse Reactions
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Agnosia
1
Interventions
Vitamin D
2
Tirzepatide
2
Metformin
2
licogliflozin
1
indole-3-carbinol
1
bupropion hydrochloride, naltrexone hydrochoride drug combination
1
Tablets
1
Specimen Handling
1
Resistance Training
1
Progestins
1
Pregabalin
1
Orlistat
1
Organizational Objectives
1
Omeprazole
1
Observation
1
Naltrexone
1
Ketorolac
1
Exergaming
1
Exercise
1
Exenatide
1
Diet, Plant-Based
1
Dexmedetomidine
1
Dalteparin
1
Counseling
1
Cholecalciferol
1
Calcium Citrate
1
Calcium Carbonate
1
Calcitriol
1
CKD732
1
Bupropion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Obesity
×
Pregabalin
×
Clear all
NCT06150898
2025-06-13
KePreSt
Jules Bordet Institute
Phase 2
Recruiting
112 enrolled